Current Report Filing (8-k)
March 28 2023 - 6:32AM
Edgar (US Regulatory)
0001581280
false
0001581280
2023-03-23
2023-03-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
March 23, 2023
Twist Bioscience Corporation
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38720 |
|
46-2058888 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I. R. S. Employer
Identification No.) |
681 Gateway Boulevard
South San Francisco, CA 94080
(Address of principal executive offices, including
ZIP code)
(800) 719-0671
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock |
|
TWST |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 23, 2023, Kevin Yankton, Chief Accounting Officer
of Twist Bioscience Corporation (the “Company”), provided notice of his resignation from the Company effective
May 19, 2023, to pursue other interests. Mr. Yankton’s resignation is not a result of any disagreement with the Company on any matter relating
to the Company’s financial reporting, operations, policies or practices. The Company has initiated a search for Mr. Yankton’s successor and, in the interim, has engaged an expert financial consultant who
will report to James Thorburn. Mr. Thorburn will serve as the Company’s principal accounting officer until a successor to Mr. Yankton
is appointed, in addition to his current role as the Company’s Chief Financial Officer.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 28, 2023 |
Twist Bioscience Corporation |
|
|
|
/s/ William E. Solis |
|
William E. Solis |
|
Deputy General Counsel and Assistant Secretary |
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024